Alper Biotech is a biotechnology company specializing in the identification, development and commercialization of novel highly-specific monoclonal antibody-based diagnostic assays in cancer.
Alper's monoclonal antibodies uniquely recognize proteins that are modified and differentially expressed in cancer cells. This novel and proprietary approach to cancer diagnostics will be applied to a variety of reindexsearch and clinical testing applications.
Alper's pipeline of cancer diagnostic kits will cover many tumor types starting with breast cancer and expanding into other tumors of major concern to Oncologists. Alper's monoclonal antibodies are selected to help address high unmet medical needs in managing cancer diagnosis and therapy today.
Dr. Alper was the first researcher to show the secretion of aberrant HER-2 from human breast cancer cells. She received the Princess Takamatsu Foundation award for the Promotion of Cancer research for this ground-breaking work.
Prior to founding Alper Biotech she served in a number of capacities with the FDA and NIH. She holds degrees from Hacettepe University and Tokyo University.
Sign In
View Cart
Help Desk
